Evaluation of the effectiveness of adjuvant therapy for Helicobacter pylori-associated diseases

The aim of the study was to compare the efficacy and safety of ET in an adjuvant regimen using the Helinorm metabiotic in combination with antihelicobacter therapy in patients with H. pylori-associated stomach diseases. Materials and methods. 60 patients with a verified diagnosis of H. pylori-associated chronic gastritis (HCG) type B and duodenal ulcer (duodenal ulcer) in the acute stage were examined, divided into 2 groups by random sampling. The first group of patients took proton pump inhibitors (PPIs) in a doubled dose, amoxicillin 2.0 g per day, clarithromycin 1.0 g per day for 14 days, the second group of patients also took metabiotic Helinorm against the background of similar therapy. The antisecretory efficacy of the drugs was assessed by topographic pH measurement, and the diagnosis and assessment of H. pylori eradication according to the Maastricht Consensus was performed using a noninvasive, C14 urease respiratory test (HUBT-20P). Results. Study has shown that when metabiotic was included in the complex of eradication therapy, there was a significant decrease in the frequency of dyspeptic side effects from the use of antibacterial drugs. This was due to an increase in the content of lacto- and bifidobacteria in the intestine and suppression of the growth of opportunistic microflora. Conclusion: Metabiotic Helinorm has high eradication activity, good tolerability and absence of side effects, and may be recommended for inclusion in the scheme of H. pylori eradication therapy for associated diseases of the gastrointestinal tract.